These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 19780621)

  • 21. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
    Chen H; Parkinson JA; Morris RE; Sadler PJ
    J Am Chem Soc; 2003 Jan; 125(1):173-86. PubMed ID: 12515520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Half-sandwich RuII-[9]aneS3 complexes with dicarboxylate ligands: synthesis, characterization and chemical behavior.
    Bratsos I; Birarda G; Jedner S; Zangrando E; Alessio E
    Dalton Trans; 2007 Sep; (36):4048-58. PubMed ID: 17828366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes.
    Liu Z; Salassa L; Habtemariam A; Pizarro AM; Clarkson GJ; Sadler PJ
    Inorg Chem; 2011 Jun; 50(12):5777-83. PubMed ID: 21618978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruthenium(II) and ruthenium(IV) complexes containing kappa1-P-, kappa2-P,O-, and kappa3-P,N,O-iminophosphorane-phosphine ligands Ph2PCH2P[=NP(=O)(OR)2]Ph2 (R = Et, Ph): synthesis, reactivity, theoretical studies, and catalytic activity in transfer hydrogenation of cyclohexanone.
    Cadierno V; Crochet P; Díez J; García-Alvarez J; García-Garrido SE; Gimeno J; García-Granda S; Rodríguez MA
    Inorg Chem; 2003 May; 42(10):3293-307. PubMed ID: 12739971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel half-sandwich Ru(II)-hydroxamate complexes: synthesis, characterization and equilibrium study in aqueous solution.
    Buglyó P; Farkas E
    Dalton Trans; 2009 Oct; (38):8063-70. PubMed ID: 19771370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
    Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
    Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.
    Liu HK; Wang F; Parkinson JA; Bella J; Sadler PJ
    Chemistry; 2006 Aug; 12(23):6151-65. PubMed ID: 16807967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
    Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
    Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex formation between Ru(η(6)-p-cym)(H2O)3]2+ and (O,O) donor ligands with biological relevance in aqueous solution.
    Bíró L; Farkas E; Buglyó P
    Dalton Trans; 2010 Nov; 39(42):10272-8. PubMed ID: 20922244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action.
    Das S; Sinha S; Britto R; Somasundaram K; Samuelson AG
    J Inorg Biochem; 2010 Feb; 104(2):93-104. PubMed ID: 19913918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimalarial activity of ruthenium(II) and osmium(II) arene complexes with mono- and bidentate chloroquine analogue ligands.
    Ekengard E; Glans L; Cassells I; Fogeron T; Govender P; Stringer T; Chellan P; Lisensky GC; Hersh WH; Doverbratt I; Lidin S; de Kock C; Smith PJ; Smith GS; Nordlander E
    Dalton Trans; 2015 Nov; 44(44):19314-29. PubMed ID: 26491831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
    Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
    Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
    Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
    J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
    Barry NP; Edafe F; Therrien B
    Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin.
    Grguric-Sipka S; Stepanenko IN; Lazic JM; Bartel C; Jakupec MA; Arion VB; Keppler BK
    Dalton Trans; 2009 May; (17):3334-9. PubMed ID: 19421637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
    Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
    van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
    J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of cancer cell growth by ruthenium complexes.
    Iida J; Bell-Loncella ET; Purazo ML; Lu Y; Dorchak J; Clancy R; Slavik J; Cutler ML; Shriver CD
    J Transl Med; 2016 Feb; 14():48. PubMed ID: 26867596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.